These findings were not in line with the outcomes of an earlier gene therapy clinical trial, in which hemophilia B patients treated with factor IX expressing AAV2 vectors exhibited a decline in therapeutic factor IX levels and an increase in hepatic transaminases [13]. Here, F9 is linked to hemophilia B.